CDCP1 protein
- Known as:
- CDCP1 protein
- Catalog number:
- 80R-4403
- Product Quantity:
- 10 ug
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- CDCP1 protein
Related genes to: CDCP1 protein
- Gene:
- CDCP1 NIH gene
- Name:
- CUB domain containing protein 1
- Previous symbol:
- -
- Synonyms:
- CD318, SIMA135
- Chromosome:
- 3p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-24
- Date modifiied:
- 2016-10-05
Related products to: CDCP1 protein
Related articles to: CDCP1 protein
- Triple-negative breast cancer (TNBC) is associated with recurrence, metastasis, and limited durable responses to immunotherapy, in part due to persistence of breast cancer stem cells (BCSCs). We investigated whether CD6-directed immunotherapy with the monoclonal antibody UMCD6 enhances immune-mediated killing and alters function of BCSC in stem cell-enriched TNBC models. The SUM-149 and SUM-159 cell lines were analyzed for CD6 ligand expression, cocultured with human peripheral blood mononuclear cells (PBMCs) treated with UMCD6, pembrolizumab, or isotype control, and assessed by live-cell cytotoxicity imaging, flow cytometry, soft agar colony formation, and extreme limiting dilution sphere assays. Both TNBC lines co-expressed the CD6 ligands CD44, CD166/ALCAM, and CD318/CDCP1. UMCD6 significantly increased PBMC-mediated apoptosis and reduced tumor cell survival in both models, with greater activity than pembrolizumab under these in vitro conditions. In surviving SUM-159 cells, UMCD6 reduced the ALDH population wit×hout significantly altering CD44CD24 frequency, indicating preferential effects on a distinct stem-like compartment. Functionally, UMCD6 decreased anchorage-independent colony formation and reduced sphere-forming frequency from 1/33.6 to 1/68.3 cells ( = 0.0186). These findings identify the CD6 ligand axis as a therapeutic vulnerability in BCSC-enriched TNBC and support further preclinical evaluation of CD6-directed immunotherapy as a strategy to enhance antitumor immunity while limiting tumor-initiating capacity. - Source: PubMed
Publication date: 2026/08/17
Gurrea-Rubio MikelSloan SophieChada AdityaAmarista Camila IMaeda KoheiCampbell Phillip LTsou Pei-SuenCooney Laura AWicha Max SFox David A - The CD6 cell surface glycoprotein is expressed by almost all T cells, a small subset of B cells and a substantial proportion of human natural killer (NK) cells. CD6 has multiple ligands and multiple functional epitopes. It is a component of the immunological synapse, and can positively or negatively influence signal transduction in T cells through complex interactions with multiple kinases and adapter molecules. Antibodies to CD6 are effective in the treatment of autoimmune diseases in experimental systems and in humans. The recent discovery that CD318 (CDCP1), a driver molecule in many cancers, is a ligand for CD6 has prompted investigation of CD6 as a possible new target for immunotherapy of cancer. A monoclonal antibody to CD6 rapidly internalizes CD6 and alters gene expression in CD8+ T cells and NK cells to augment the cytotoxicity of human lymphocytes to human cancer cells from a range of neoplasms. This review, using a question and answer format, describes recent work on anti-CD6 as a candidate immunotherapy for cancer as well as relevant advances in our understanding of other aspects of the biology of CD6, and explores the possibility that this approach could avoid the autoimmune complications that are encountered with checkpoint inhibitor treatment of cancer. - Source: PubMed
Publication date: 2026/08/11
Fox David AGurrea-Rubio Mikel - Endometriosis (EM) is a chronic inflammatory gynaecological disorder affecting approximately 10% of women of reproductive age. Early diagnosis remains challenging because definitive diagnosis still relies on invasive surgical confirmation. This study aimed to characterize systemic immune-metabolic alterations in EM and identify candidate peripheral blood biomarkers through integrated multi-omics profiling. - Source: PubMed
Publication date: 2026/08/11
Pan WenweiLyu GuizhenWang YikangChen TingtingLiu SainanFan XinyiLiu RuibinLin HaochaoLi GuanxiaSu XiaofengZhou Ping - CUB domain-containing protein 1 (CDCP1) is an emerging tumor-associated surface antigen broadly expressed in solid tumors and linked to poor prognosis, making it an attractive target for selective therapeutic delivery. We evaluated CDCP1 as a platform for two distinct therapeutic modalities: an antibody-drug conjugate (ADC) for cytotoxic payload delivery and an immunocytokine for targeted delivery of interferon-α2b (IFNα2b). - Source: PubMed
Publication date: 2026/08/17
Mu GuangmaoYu MingcanZhou FulaiBi HongleiZha ZhengxiaHuang ShengJin YingHan ChaoChiu Mark LZhang Di - The Bacillus Calmette-Guérin (BCG) vaccine, primarily designed for tuberculosis, exerts non-specific immunological effects that vary considerably among children. Limited knowledge exists regarding genetic variants that can impact immune responses post-vaccination. Understanding the genetic factors influencing the immune response in children following BCG vaccination is crucial for optimizing vaccine strategies. Genome-wide pQTL mapping of 65 circulating inflammatory proteins profiled at Month 13 uncovered 11 independent genome-wide significant loci. Following pQTL mapping in BCG-unvaccinated children, whose mean age was not significantly different from that of BCG-vaccinated children, a P-value lookup complemented with statistical colocalization and interaction analyses identified four pQTLs (rs10217747: CXCL11, rs13187850: CD6, rs56283092: LAP-TGF-beta 1, and rs11708321: CDCP1) showing evidence of genotype-by-BCG interactions and larger effect estimates in the BCG group. These variants have previously been associated with inflammatory and autoimmune traits. Genetic analysis of in vitro cytokine production capacity after BCG vaccination identified nominal associations mainly at Month 13 rather than Day 4 or Month 3. These findings enhance our understanding of immune responses to vaccination in children but, given the exploratory genome-wide approach, should be considered hypothesis-generating and require further validation. - Source: PubMed
Publication date: 2026/08/13
Boahen Collins KNissen Thomas NBirk Nina MNetea Mihai GBenn Christine StabellKumar Vinod